<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">JCO Precis Oncol</journal-id>
        <journal-id journal-id-type="pmc-domain-id">3882</journal-id>
        <journal-id journal-id-type="pmc-domain">jcopo</journal-id>
        <journal-id journal-id-type="publisher-id">PO</journal-id>
        <journal-title-group>
          <journal-title>JCO Precision Oncology</journal-title>
        </journal-title-group>
        <issn pub-type="epub">2473-4284</issn>
        <publisher>
          <publisher-name>American Society of Clinical Oncology</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC7446400</article-id>
        <article-id pub-id-type="pmcid-ver">PMC7446400.1</article-id>
        <article-id pub-id-type="pmcaid">7446400</article-id>
        <article-id pub-id-type="pmcaiid">7446400</article-id>
        <article-id pub-id-type="pmid">32913971</article-id>
        <article-id pub-id-type="doi">10.1200/PO.16.00054</article-id>
        <article-id pub-id-type="publisher-id">1600054</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Original Reports</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title><italic toggle="yes">PTEN</italic> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Catalanotti</surname>
              <given-names initials="F">Federica</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Cheng</surname>
              <given-names initials="DT">Donavan T.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Shoushtari</surname>
              <given-names initials="AN">Alexander N.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Johnson</surname>
              <given-names initials="DB">Douglas B.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Panageas</surname>
              <given-names initials="KS">Katherine S.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Momtaz</surname>
              <given-names initials="P">Parisa</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Higham</surname>
              <given-names initials="C">Catherine</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Won</surname>
              <given-names initials="HH">Helen H.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Harding</surname>
              <given-names initials="JJ">James J.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Merghoub</surname>
              <given-names initials="T">Taha</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Rosen</surname>
              <given-names initials="N">Neal</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sosman</surname>
              <given-names initials="JA">Jeffrey A.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Berger</surname>
              <given-names initials="MF">Michael F.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chapman</surname>
              <given-names initials="PB">Paul B.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
            <xref ref-type="corresp" rid="cor1"/>
          </contrib>
          <aff id="aff1"><bold>Federica</bold>
<bold>Catalanotti</bold>, <bold>Donavan T. Cheng</bold>, <bold>Alexander N. Shoushtari</bold>, <bold>Katherine S. Panageas</bold>, <bold>Parisa Momtaz</bold>, <bold>Helen H. Won</bold>, <bold>James J. Harding</bold>, <bold>Taha Merghoub</bold>, <bold>Neal Rosen</bold>, <bold>Michael F. Berger</bold>, <bold>Paul B. Chapman</bold>, and <bold>David B. Solit</bold>, Memorial Sloan Kettering Cancer Center, New York, NY; <bold>Douglas B. Johnson</bold>, <bold>Catherine Higham</bold>, and <bold>Jeffrey A. Sosman</bold>, Vanderbilt University Medical Center; and <bold>Douglas B. Johnson</bold> and <bold>Jeffrey A. Sosman</bold>, Vanderbilt-Ingram Cancer Center, Nashville, TN.</aff>
        </contrib-group>
        <author-notes>
          <fn id="afn1" fn-type="equal">
            <p>F.C. and D.T.C. contributed equally to the work.</p>
          </fn>
          <corresp id="cor1"><bold>Corresponding author:</bold> David B. Solit, MD, Memorial Sloan Kettering Cancer Center, 417 E 68th St, New York, NY 10065; e-mail: <email>solitd@mskcc.org</email>.</corresp>
        </author-notes>
        <pub-date pub-type="collection">
          <year>2017</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>23</day>
          <month>6</month>
          <year>2017</year>
        </pub-date>
        <volume>1</volume>
        <issue-id pub-id-type="pmc-issue-id">363914</issue-id>
        <elocation-id>PO.16.00054</elocation-id>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>23</day>
              <month>06</month>
              <year>2018</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>09</day>
              <month>09</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2020-09-30 22:56:28.270">
              <day>30</day>
              <month>09</month>
              <year>2020</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>Â© 2017 by American Society of Clinical Oncology</copyright-statement>
          <copyright-year>2017</copyright-year>
          <copyright-holder>American Society of Clinical Oncology</copyright-holder>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PO.16.00054.pdf"/>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:title="pdf" xlink:href="PO.16.00054.pdf"/>
        <abstract>
          <sec>
            <title>Purpose</title>
            <p>The clinical use of BRAF inhibitors in patients with melanoma is limited by intrinsic and acquired resistance. We asked whether next-generation sequencing of pretreatment tumors could identify coaltered genes that predict for intrinsic resistance to BRAF inhibitor therapy in patients with melanoma as a prelude to rational combination strategies.</p>
          </sec>
          <sec>
            <title>Patients and Methods</title>
            <p>We analyzed 66 tumors from patients with metastatic <italic toggle="yes">BRAF</italic>-mutant melanoma collected before treatment with BRAF inhibitors. Tumors were analyzed for &gt; 250 cancer-associated genes using a capture-based next-generation sequencing platform. Antitumor responses were correlated with clinical features and genomic profiles with the goal of identifying a molecular signature predictive of intrinsic resistance to RAF pathway inhibition.</p>
          </sec>
          <sec>
            <title>Results</title>
            <p>Among the 66 patients analyzed, 11 received a combination of BRAF and MEK inhibitors for the treatment of melanoma. Among the 55 patients treated with BRAF inhibitor monotherapy, objective responses, as assessed by Response Evaluation Criteria in Solid Tumors (RECIST), were observed in 30 patients (55%), with five (9%) achieving a complete response. We identified a significant association between alterations in <italic toggle="yes">PTEN</italic> that would be predicted to result in loss of function and reduced progression-free survival, overall survival, and response grade, a metric that combines tumor regression and duration of treatment response. Patients with melanoma who achieved an excellent response grade were more likely to have an elevated <italic toggle="yes">BRAF</italic>-mutant allele fraction.</p>
          </sec>
          <sec>
            <title>Conclusion</title>
            <p>These results provide a rationale for cotargeting BRAF and the PI3K/AKT pathway in patients with <italic toggle="yes">BRAF</italic>-mutant melanoma when tumors have concurrent loss-of-function mutations in <italic toggle="yes">PTEN</italic>. Future studies should explore whether gain of the mutant <italic toggle="yes">BRAF</italic> allele and/or loss of the wild-type allele is a predictive marker of BRAFi sensitivity.</p>
          </sec>
        </abstract>
        <counts>
          <fig-count count="4"/>
          <table-count count="5"/>
          <equation-count count="0"/>
          <ref-count count="50"/>
          <page-count count="15"/>
        </counts>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name> SJS Export </meta-name>
            <meta-value>v1</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
